{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:23:47Z","timestamp":1787761427234,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006012","name":"Christian Doppler Forschungsgesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver fibrosis and portal hypertension (PH) determine prognosis in chronic liver disease. In experimental models, stimulation of NO\u2013sGC\u2013cGMP signaling improved fibrosis, PH and inflammation. Since fibrosis and PH improve slowly after injury cessation, we investigated whether stimulating sGC activity accelerates their regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Liver fibrosis was induced in C57BL\/6\u00a0J mice by either carbon tetrachloride (CCl\n                      <jats:sub>4<\/jats:sub>\n                      ; 2\u00a0\u00b5l\/g,\u00a0gavage 3x\/week) for 12\u00a0weeks or thioacetamide (TAA; 150\u00a0mg\/kg, intraperitoneal injections 3x\/week) for 12\u00a0weeks, followed by 1 (R1) or 2 (R2) weeks of regression. Animals received the sGC stimulator Riociguat (RIO; 3\u00a0mg\/kg, gavage 2x\/day) during regression. Disease severity was assessed by portal pressure (PP), collagen proportionate area (CPA) and whole liver transcriptomics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PH and fibrosis area peaked in the TAA model at 7.71\u2009\u00b1\u20090.57\u00a0mmHg PP and 3.87\u2009\u00b1\u20090.19% CPA; and in the CCl\n                      <jats:sub>4<\/jats:sub>\n                      \u00a0model at 9.06\u2009\u00b1\u20090.89\u00a0mmHg PP and 9.43\u2009\u00b1\u20092.59% CPA, respectively; followed by spontaneous regression at R2 (TAA:\u00a0PP: 6.04\u2009\u00b1\u20090.52\u00a0mmHg, CPA: 2.90\u2009\u00b1\u20090.30%; CCl\n                      <jats:sub>4<\/jats:sub>\n                      :\u00a0PP: 5.88\u2009\u00b1\u20090.52\u00a0mmHg, CPA: 6.66\u2009\u00b1\u20091.45%). RIO significantly increased hepatic cGMP levels (CCl\n                      <jats:sub>4<\/jats:sub>\n                      \u2013R2: 5.89\u2009\u00b1\u20090.58\u00a0nmol\/L, R2\u2009+\u2009RIO: 12.41\u2009\u00b1\u20091.98\u00a0nmol\/L). While fibrosis and PH regression were not significantly different, RIO treatment attenuated the hepatic pro-inflammatory gene signatures in both models and improved metabolic pathways on a transcriptional level.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Riociguat increases hepatic cGMP bioavailability and mitigates inflammatory and metabolic gene signatures in two experimental models of regressive liver disease. While regression of liver fibrosis and PH was not accelerated by Riociguat, our results suggest beneficial effects of sGC stimulation during regressive liver disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12072-026-11086-4","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:09:00Z","timestamp":1776276540000},"page":"1116-1126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of pharmacological sGC stimulation with Riociguat in experimental models of liver disease regression"],"prefix":"10.1007","volume":"20","author":[{"given":"Katharina","family":"Bonitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"K\u00f6nigshofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Horstmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sorz-Nechay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Taru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Bareiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksander","family":"Petrenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Simbrunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt Silvester","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Zinober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Regnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Scharnagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kauscke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwabl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"11086_CR1","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jhep.2024.06.016","volume":"81","author":"V Taru","year":"2024","unstructured":"Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation. J Hepatol. 2024;81:895\u2013910","journal-title":"J Hepatol"},{"key":"11086_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18:151\u2013166. https:\/\/doi.org\/10.1038\/s41575-020-00372-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"11086_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1055\/s-0039-1693115","volume":"39","author":"K Brusilovskaya","year":"2019","unstructured":"Brusilovskaya K, K\u00f6nigshofer P, Schwabl P, Reiberger T. Vascular targets for the treatment of portal hypertension. Semin Liver Dis. 2019;39:483\u2013501","journal-title":"Semin Liver Dis"},{"key":"11086_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","volume":"66","author":"J Poisson","year":"2017","unstructured":"Poisson J, et al. Liver sinusoidal endothelial cells: physiology and role in liver diseases. J Hepatol. 2017;66:212\u2013227","journal-title":"J Hepatol"},{"key":"11086_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bpg.2017.04.005","volume":"31","author":"ME Zoubek","year":"2017","unstructured":"Zoubek ME, Trautwein C, Strnad P. Reversal of liver fibrosis: from fiction to reality. Best Pract Res: Clin Gastroenterol. 2017;31:129\u2013141. https:\/\/doi.org\/10.1016\/j.bpg.2017.04.005","journal-title":"Best Pract Res: Clin Gastroenterol"},{"key":"11086_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.jhep.2011.09.024","volume":"56","author":"EL Ellis","year":"2012","unstructured":"Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012;56:1171\u20131180","journal-title":"J Hepatol"},{"key":"11086_CR7","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jhep.2011.02.012","volume":"55","author":"M Young Kim","year":"2011","unstructured":"Young Kim M. et al. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol. 2011;55:1004\u20131009. https:\/\/doi.org\/10.1016\/j.jhep.2011.02.012.","journal-title":"J Hepatol"},{"key":"11086_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biology11081160","volume":"11","author":"A Armandi","year":"2022","unstructured":"Armandi A, et al. Changes in liver stiffness and markers of liver synthesis and portal hypertension following hepatitis C virus eradication in cirrhotic individuals. Biology. 2022;11: 1160","journal-title":"Biology"},{"key":"11086_CR9","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","volume":"74","author":"Z Boyer-Diaz","year":"2021","unstructured":"Boyer-Diaz Z, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol. 2021;74:1188\u20131199","journal-title":"J Hepatol"},{"key":"11086_CR10","doi-asserted-by":"publisher","first-page":"E3186","DOI":"10.1073\/pnas.1119964109","volume":"109","author":"P Ramachandran","year":"2012","unstructured":"Ramachandran P, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci USA. 2012;109:E3186","journal-title":"Proc Natl Acad Sci USA"},{"key":"11086_CR11","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.4049\/jimmunol.178.8.5288","volume":"178","author":"JA Fallowfield","year":"2007","unstructured":"Fallowfield JA, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol. 2007;178:5288\u20135295","journal-title":"J Immunol"},{"key":"11086_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1172\/JCI1018","volume":"102","author":"JP Iredale","year":"1998","unstructured":"Iredale JP, et al. Mechanisms of spontaneous resolution of rat liver fibrosis Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Investig. 1998;102:538","journal-title":"J Clin Investig"},{"key":"11086_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12381-0","author":"T Sorz-Nechay","year":"2025","unstructured":"Sorz-Nechay T, et al. Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis models. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-025-12381-0","journal-title":"Sci Rep"},{"key":"11086_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1515\/hsz-2018-0155","volume":"399","author":"P Sandner","year":"2018","unstructured":"Sandner P. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators. Biol Chem. 2018;399:679\u2013690","journal-title":"Biol Chem"},{"key":"11086_CR15","doi-asserted-by":"publisher","first-page":"10372","DOI":"10.3390\/ijms221910372","volume":"22","author":"W Kreisel","year":"2021","unstructured":"Kreisel W, et al. Cyclic GMP in liver cirrhosis\u2014role in pathophysiology of portal hypertension and therapeutic implications. Int J Mol Sci. 2021;22:10372","journal-title":"Int J Mol Sci"},{"key":"11086_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","volume":"122","author":"P Sandner","year":"2017","unstructured":"Sandner P, Stasch JP. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Respir Med. 2017;122:S1\u2013S9","journal-title":"Respir Med"},{"key":"11086_CR17","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/bph.14137","volume":"175","author":"R Flores-Costa","year":"2018","unstructured":"Flores-Costa R, et al. The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. Br J Pharmacol. 2018;175:953\u2013967","journal-title":"Br J Pharmacol"},{"key":"11086_CR18","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1177\/2050640620944140","volume":"8","author":"K Brusilovskaya","year":"2020","unstructured":"Brusilovskaya K, et al. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. United Eur Gastroenterol J. 2020;8:1174\u20131185","journal-title":"United Eur Gastroenterol J"},{"key":"11086_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27656-y","author":"P Schwabl","year":"2018","unstructured":"Schwabl P, et al. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Sci Rep. 2018. https:\/\/doi.org\/10.1038\/s41598-018-27656-y","journal-title":"Sci Rep"},{"key":"11086_CR20","doi-asserted-by":"publisher","first-page":"11057","DOI":"10.1073\/pnas.1821045116","volume":"166","author":"KC Hall","year":"2019","unstructured":"Hall KC, et al. SGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH. Proc Natl Acad Sci USA. 2019;166:11057\u201311062","journal-title":"Proc Natl Acad Sci USA"},{"key":"11086_CR21","doi-asserted-by":"publisher","unstructured":"Conole D, Scott LJ. Riociguat: First Global Approval. https:\/\/doi.org\/10.1007\/s40265-013-0149-5","DOI":"10.1007\/s40265-013-0149-5"},{"key":"11086_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1124\/jpet.122.001532","volume":"386","author":"AK Jones","year":"2023","unstructured":"Jones AK, et al. Soluble guanylyl cyclase activator BI 685509 reduces portal hypertension and portosystemic shunting in a rat thioacetamide-induced cirrhosis model. J Pharmacol Exp Ther. 2023;386:70\u201379","journal-title":"J Pharmacol Exp Ther"},{"key":"11086_CR23","doi-asserted-by":"publisher","first-page":"28263","DOI":"10.1073\/pnas.2000466117","volume":"117","author":"R Flores-Costa","year":"2020","unstructured":"Flores-Costa R, et al. Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP\/ NF-\u03baB\/NLRP3 inflammasome circuit. Proc Natl Acad Sci USA. 2020;117:28263\u201328274","journal-title":"Proc Natl Acad Sci USA"},{"key":"11086_CR24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.12.017","author":"G Xie","year":"2012","unstructured":"Xie G, et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology. 2012. https:\/\/doi.org\/10.1053\/j.gastro.2011.12.017","journal-title":"Gastroenterology"},{"key":"11086_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13063-023-07291-3","volume":"24","author":"T Reiberger","year":"2023","unstructured":"Reiberger T, et al. The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis. Trials. 2023;24:293","journal-title":"Trials"},{"key":"11086_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.bbadis.2018.07.018","volume":"1865","author":"P K\u00f6nigshofer","year":"2019","unstructured":"K\u00f6nigshofer P, Brusilovskaya K, Schwabl P, Reiberger T. Animal models of portal hypertension. Biochimica et Biophysica Acta (BBA). 2019;1865:1019\u20131030","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"11086_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jchromb.2008.12.063","volume":"877","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, et al. Development and validation of an LC\u2013MS\/MS method for quantification of cyclic guanosine 3\u2032,5\u2032-monophosphate (cGMP) in clinical applications: A comparison with a EIA method. J Chromatogr B Biomed Sci Appl. 2009;877:513\u2013520","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"11086_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550","journal-title":"Genome Biol"},{"key":"11086_CR29","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1093\/nar\/gky221","volume":"46","author":"DS Fischer","year":"2018","unstructured":"Fischer DS, Theis FJ, Yosef N. Impulse model-based differential expression analysis of time course sequencing data. Nucleic Acids Res. 2018;46:e119","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"11086_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/ni.2670","volume":"2013","author":"ZG Ramirez-Ortiz","year":"2013","unstructured":"Ramirez-Ortiz ZG, et al. The scavenger receptor SCARF1 mediates the clearance of apoptotic cells and prevents autoimmunity. Nature Immunol. 2013;2013(14):917\u2013926","journal-title":"Nature Immunol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11086-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11086-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11086-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:40:58Z","timestamp":1787758858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11086-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11086"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11086-4","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BS received travel support by AbbVie, Gilead, and Falk. HS has received research grants and support from Abbott Diagnostics and Amgen and honoraria from Amgen and Sanofi. PS, ES and SK are employed by Boehringer Ingelheim Pharma GmbH & Co.KG. MT received grant support from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx, honoraria for consulting from AbbVie, Albireo, Agomab, Alfasigma, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Jannsen, MSD, Mirum, Novartis, Phenex, Pliant, ProQR Therapeutics, Regulus, Siemens and Shire, speaker fees from Albireo, Boehringer Ingelheim, Bristol-Myers Squibb, Falk, Gilead, Ipsen, Intercept, Madrigal, MSD and Mirum, as well as travel support from AbbVie, Falk, Gilead, Jannsen, Intercept and Ipsen. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid (service inventions as university employee) filed by the Medical University of Graz. TR received grant support from Abbvie, Boehringer Ingelheim, Gilead, Intercept\/Advanz Pharma, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L. Gore & Associates; speaking\/writing honoraria from Abbvie, Echosens, Gilead, GSK, Intercept\/Advanz Pharma, Pfizer, Roche, MSD, Siemens, W. L. Gore & Associates; consulting\/advisory board fee from Abbvie, Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Intercept\/Advanz Pharma, MSD, Resolution Therapeutics, Siemens; and travel support from Abbvie, Boehringer Ingelheim, Dr. Falk Pharma, Gilead, and Roche. PS received speaking\/writing honoraria from Falk Pharma; consulting\/advisory board fee from PharmaIN; and travel support from Falk Pharma. KBo, PK, HH, TS-N, VT, KBa, OP, BSH, GK, KS, KZ and KR declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}